Shandong Simcere Medgenn Bio-Pharmaceutical discloses new KRAS G12D inhibitors

July 30, 2026

Shandong Simcere Medgenn Bio-Pharmaceutical Co. Ltd. has reported GTPase KRAS (G12D mutant) inhibitors found to be useful for the treatment of non-small-cell lung and pancreatic cancer.

BioWorld Science Cancer Patents

Today's news in brief

BioWorld

BioWorld briefs for July 30, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for July 28, 2026

Illustration of dopamine signaling in the brain

New schizophrenia targets challenge trial design

BioWorld

The search for better schizophrenia therapies is moving beyond dopamine toward a growing number of experimental targets. According to researchers, the repeated...

AIDS 2026: New targets for metabolic dysfunction despite ART

BioWorld

Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...

Regulatory actions for July 27, 2026

BioWorld

Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Alfasigma,...